Appln. No. 09/989,388 Amd. dated October 9, 2003 Reply to Office Action of July 15, 2003

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A Lys-Lys binding site I which is a plasminogen fragment consisting of Kringle 1 to Kringle 3 of a naturally occurring plasminogen with the N-terminal being lysine, which binding site binds to heparin and has the following properties:

- a. a molecular weight of 38 kDa;
- b. it is not glycosylated;
- c. it binds intensely to heparin at pH lower than neutral pH but does not bind to heparin at neutral or higher pH, under non-physiological conditions but binds less intensely to heparin under physiological conditions;
- d. it inhibits tumor metastasis and tumor growth but has no ability to inhibit growth of endothelial cells of blood vessels;

wherein said plasminogen fragment is prepared by;

a. preparing Lys-plasminogen from naturally occurringhuman plasminogen either by adding plasminogen to a

Appln. No. 09/989,388 Amd. dated October 9, 2003 Reply to Office Action of July 15, 2003

solution of naturally occurring plasminogen or by incubating naturally occurring plasminogen in the presence of transexamic acid to autolysis;

- b. treating the Lys-plasminogen obtained in step

 (a) with the elastase to produce fractions of the fragment

 comprising Kringle 1 to Kringle 3;
- c. identifying the fragment of Kringle 1 to Kringle 3 which binds to heparin.

Claim 2 (Currently amended): A process for preparing a plasminogen fragment consisting of Kringle 1 to Kringle 3 of a naturally occurringhuman plasminogen with the N-terminal being lysine, said fragment having the ability to inhibit tumor growth, but having no ability to inhibit growth of endothelial cells of blood vessels, comprising;

- a. preparing Lys-plasminogen from naturally occurring plasminogen either by adding plasmin to a solution of naturally occurring plasminogen or by incubating naturally occurring plasminogen in the presence of tranexamic acid to autolysis;
- b. treating the Lys-plasminogen obtained in step
 (a) with elastase to produce fractions of the fragment
 consisting of Kringle 1 to Kringle 3;

Appln. No. 09/989,388 Amd. dated October 9, 2003 Reply to Office Action of July 15, 2003

- c. identifying the fragment of Kringle 1 to Kringle 3 which binds to heparin; and
 - d. isolating the fragment which binds to heparin.

Claim 3 (Currently amended): The process according to claim 2 wherein the fragment which bind binds to heparin is recovered by passing a solution of a Lys-plasminogen lysate with elastase through a carrier to which heparin is coupled as a ligand to adsorb those fragment fragments which bind to heparin, and eluting those fragments which do not bind to heparin.

Claim 4 (Currently amended): A composition for inhibiting <u>lung</u> tumor metastasis and <u>lung</u> tumor growth comprising an effective amount of a fragment according to claim 1 and, optionally, a pharmaceutically acceptable carrier.